CPRX - Catalyst Pharmaceuticals appoints Kalb as its CFO
2023-12-04 08:22:02 ET
More on Catalyst Pharmaceuticals
- Catalyst Pharmaceuticals: Agamree Approval Selloff A Long-Term Buying Opportunity
- Catalyst Pharmaceuticals Non-GAAP EPS of $0.49 beats by $0.48, revenue of $102.7M beats by $2.33M
For further details see:
Catalyst Pharmaceuticals appoints Kalb as its CFO